RXi Pharmaceuticals makes appointment
This article was originally published in Scrip
Executive Summary
RXi Pharmaceuticals, a US biopharmaceutical company focused on the development and commercialisation of proprietary therapeutics based on RNA interference (RNAi), has appointed Dr Anastasia Khvorova to the newly created position of chief scientific officer. Dr Khvorova previously served as CSO at Dharmacon (now a Thermo Fisher Scientific company).